In Reply

Affiliations

¹ Division of Bone, Reproductive, and Urologic Products, Office of Drug Evaluation III, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, Maryland.
² Division of Pharmacovigilance II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology and Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

Comment

Catherine A Sewell et al. Obstet Gynecol. 2017 Oct.

. 2017 Oct;130(4):913-914.

doi: 10.1097/AOG.0000000000002291.

¹ Division of Bone, Reproductive, and Urologic Products, Office of Drug Evaluation III, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, Maryland.
² Division of Pharmacovigilance II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology and Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Comment on

Domperidone for Lactation: What Health Care Providers Need to Know.
Sewell CA, Chang CY, Chehab MM, Nguyen CP. Sewell CA, et al. Obstet Gynecol. 2017 Jun;129(6):1054-1058. doi: 10.1097/AOG.0000000000002033. Obstet Gynecol. 2017. PMID: 28486375
Domperidone for Lactation: What Health Care Providers Really Should Know.
Grzeskowiak LE. Grzeskowiak LE. Obstet Gynecol. 2017 Oct;130(4):913. doi: 10.1097/AOG.0000000000002286. Obstet Gynecol. 2017. PMID: 28937559 No abstract available.

1. Sewell CA, Chang CY, Chehab MM, Nguyen CP. Domperidone for lactation: what health care providers need to know. Obstet Gynecol 2017;129:1054–8.
1. Smolina K, Mintzes B, Hanley GE, Oberlander TF, Morgan SG. The association between domperidone and ventricular arrhythmia in the postpartum period. Pharmacoepidemiol Drug Saf 2016;25:1210–4.
1. Asztalos EV, Campbell-Yeo M, da Silva OP, Ito S, Kiss A, Knoppert D. Enhancing human milk production with domperidone in mothers and preterm infants. J Hum Lact 2017;33:181–7.
1. Smolina K, Morgan S, Mintzes B, Hanley G, Oberlander T. Response to “use of domperidone and risk of ventricular arrhythmia in the postpartum period: getting to the heart of the matter”. Pharmacoepidemiol Drug Saf 2017;26:865–6.
1. Grzeskowiak LE, Smithers LG. Use of domperidone and risk of ventricular arrhythmia in the postpartum period: getting to the heart of the matter. Pharmacoepidemiol Drug Saf 2017;26:863–4.